Diabetes Forecast

The Healthy Living Magazine

FDA Clears Inhaled Insulin Afrezza

Soon there will be a new way to take premeal insulin: Inhale it. The U.S. Food and Drug Administration has cleared Afrezza, an inhaled rapid-acting insulin for adults with type 1 and type 2 diabetes. (The drug is not recommended for smokers or people with chronic lung disease.) Afrezza seems to work faster than injected rapid-acting insulin. The manufacturer, MannKind Corp., is hopeful Afrezza will succeed where the more expensive inhaled insulin Exubera failed. Afrezza has a smaller, easier-to-use inhaler than Exubera did and is expected to cost about as much as insulin pens. However, injections are still the only option for long-acting insulin.
Source: American Diabetes Association's 74th annual Scientific Sessions, June 2014.


Get Free Health Tips

Register for free recipes, news you can use, and simple health tips – delivered right to your inbox.

Get to Know

While she’s still spinning music, DJ Spinderella (aka Deidra Roper) is no longer spinning her wheels when it comes to getting the right information to help her family members who have diabetes. Read more >